MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation [PDF]
, 2015 MYCN is a transcription factor that plays key roles in both normal development and cancer. In neuroblastoma, MYCN acts as a major oncogenic driver through pleiotropic effects controlled by multiple protein encoding genes as well as microRNAs (miRNAs ...
Vandesompele, Jo +16 more
core +3 more sources
Upstream ORF affects MYCN translation depending on exon 1b alternative splicing
BMC Cancer, 2009 Background The MYCN gene is transcribed into two major mRNAs: one full-length (MYCN) and one exon 1b-spliced (MYCNΔ1b) mRNA. But nothing is known about their respective ability to translate the MYCN protein.
Tutrone Giovani +9 more
doaj +1 more source
MYCN and Metabolic Reprogramming in Neuroblastoma
Cancers, 2022 Neuroblastoma is a pediatric cancer responsible for approximately 15% of all childhood cancer deaths. Aberrant MYCN activation, as a result of genomic MYCN amplification, is a major driver of high-risk neuroblastoma, which has an overall survival rate of less than 50%, despite the best treatments currently available.
Mohit Bansal +2 more
openaire +2 more sources
Stem Cell Markers in Neuroblastoma—An Emerging Role for LGR5 [PDF]
, 2015 The prognostic value of cancer stem cell markers in various cancer subtypes is a well documented research area. Our findings show that the stem cell marker Lgr5 is associated with an aggressive phenotype in neuroblastoma.
Darren Johnson +9 more
core +1 more source
Evaluation of MYCN immunohistochemistry as a cost-effective surrogate for MYCN genetic testing
, 2022 Background: Background: MYCN amplified neuroblastomas are associated with poor prognosis. Fluorescence in-situ Hybridization (FISH) is the recommended technique to identify MYCN amplification.
Aditya Jadav +17 more
core +1 more source
Opportunities and challenges of circulating biomarkers in neuroblastoma [PDF]
Open Biology, 2019 Molecular analysis of nucleic acid and protein biomarkers is becoming increasingly common in paediatric oncology for diagnosis, risk stratification and molecularly targeted therapeutics. However, many current and emerging biomarkers are based on analysis
Ricky M. Trigg +2 more
doaj +1 more source
An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes
Frontiers in Cell and Developmental Biology, 2021 Liver regeneration is characterized by cell cycle reentrance of hepatocytes. N-Myc, encoded by MYCN, is a member of the Myc family of transcription factors.
Zhiwen Fan +18 more
doaj +1 more source
MYCN-targeting vaccines and immunotherapeutics [PDF]
Human Vaccines & Immunotherapeutics, 2016 Amplification and concomitant overexpression of the MYCN oncogene is a frequent event in many malignancies including the childhood tumors, neuroblastoma and medulloblastoma. MYCN is only expressed in a defined time frame during early developmental processes, (1) which is beneficial for approaches combatting tumor-specific MYCN.
Schramm, Alexander, Lode, Holger
openaire +3 more sources
Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma [PDF]
, 2015 Medulloblastoma (MB) is the most common malignant pediatric brain tumor. While the pathways that are deregulated in MB remain to be fully characterized, amplification and/or overexpression of theMYCNgene, which is has a critical role in cerebellar ...
Veronica Gil +23 more
core +1 more source
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma [PDF]
Cell Stress, 2022 Ferroptosis is an iron-dependent, oxidative form of cell death that is countered mainly by glutathione peroxidase 4 (GPX4) and the production of glutathione (GSH), which is formed from cysteine. The identification of the cancers that may benefit from pharmacological ferroptotic induction is just emerging.
Konstantinos V. Floros +8 more
openaire +3 more sources